Treatment of osteoarthritis with autologous, micro-fragmented adipose tissue: a study protocol for a randomized controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Treatment of osteoarthritis with autologous, micro-fragmented adipose tissue : a study protocol for a randomized controlled trial. / Mikkelsen, Rasmus Kramer; Blønd, Lars; Hölmich, Lisbeth Rosenkrantz; Mølgaard, Cecilie; Troelsen, Anders; Hölmich, Per; Barfod, Kristoffer Weisskirchner.

I: Trials, Bind 22, Nr. 1, 748, 2021.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Mikkelsen, RK, Blønd, L, Hölmich, LR, Mølgaard, C, Troelsen, A, Hölmich, P & Barfod, KW 2021, 'Treatment of osteoarthritis with autologous, micro-fragmented adipose tissue: a study protocol for a randomized controlled trial', Trials, bind 22, nr. 1, 748. https://doi.org/10.1186/s13063-021-05628-4

APA

Mikkelsen, R. K., Blønd, L., Hölmich, L. R., Mølgaard, C., Troelsen, A., Hölmich, P., & Barfod, K. W. (2021). Treatment of osteoarthritis with autologous, micro-fragmented adipose tissue: a study protocol for a randomized controlled trial. Trials, 22(1), [748]. https://doi.org/10.1186/s13063-021-05628-4

Vancouver

Mikkelsen RK, Blønd L, Hölmich LR, Mølgaard C, Troelsen A, Hölmich P o.a. Treatment of osteoarthritis with autologous, micro-fragmented adipose tissue: a study protocol for a randomized controlled trial. Trials. 2021;22(1). 748. https://doi.org/10.1186/s13063-021-05628-4

Author

Mikkelsen, Rasmus Kramer ; Blønd, Lars ; Hölmich, Lisbeth Rosenkrantz ; Mølgaard, Cecilie ; Troelsen, Anders ; Hölmich, Per ; Barfod, Kristoffer Weisskirchner. / Treatment of osteoarthritis with autologous, micro-fragmented adipose tissue : a study protocol for a randomized controlled trial. I: Trials. 2021 ; Bind 22, Nr. 1.

Bibtex

@article{874f1c83babb450c9a80680ea7a5366f,
title = "Treatment of osteoarthritis with autologous, micro-fragmented adipose tissue: a study protocol for a randomized controlled trial",
abstract = "Background: Osteoarthritis is a destructive joint disease that leads to degeneration of cartilage and other morphological changes in the joint. No medical treatment currently exists that can reverse these morphological changes. Intra-articular injection with autologous, micro-fragmented adipose tissue has been suggested to relieve symptoms. Methods/Design: The study is a blinded randomized controlled trial with patients allocated in a 1:1 ratio to 2 parallel groups. Patients suffering from pain and functional impairment due to osteoarthritis Kellgren-Lawrence grades 2–3 in the tibiofemoral joint are eligible for inclusion. The intervention group is treated with an intra-articular injection with autologous, micro-fragmented adipose tissue prepared using the Lipogems{\textregistered} system. The control group receives an intra-articular injection with isotonic saline. In total, 120 patients are to be included. The primary outcome is The Knee injury and Osteoarthritis Outcome Score (KOOS4) evaluated at 6 months. Secondary outcomes are KOOS at 3, 12 and 24 months; the Tegner activity score; treatment failure; and work status of the patient. The analysis will be conducted both as intention-to-treat and per-protocol analysis. Discussion: This trial is the first to investigate the efficacy of autologous, micro-fragmented adipose tissue in a randomized controlled trial. The study uses the patient-reported outcome measure Knee Injury and Osteoarthritis Outcome Score (KOOS4) after 6 months as the primary outcome, as it is believed to be a valid measure to assess the patient{\textquoteright}s opinion about their knee and associated problems when suffering from osteoarthritis.",
keywords = "Biologic treatment, Knee osteoarthritis, Micro-fragmented adipose tissue, MSCs, Pericyte, Randomized controlled trial, Stemcell",
author = "Mikkelsen, {Rasmus Kramer} and Lars Bl{\o}nd and H{\"o}lmich, {Lisbeth Rosenkrantz} and Cecilie M{\o}lgaard and Anders Troelsen and Per H{\"o}lmich and Barfod, {Kristoffer Weisskirchner}",
note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2021",
doi = "10.1186/s13063-021-05628-4",
language = "English",
volume = "22",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Treatment of osteoarthritis with autologous, micro-fragmented adipose tissue

T2 - a study protocol for a randomized controlled trial

AU - Mikkelsen, Rasmus Kramer

AU - Blønd, Lars

AU - Hölmich, Lisbeth Rosenkrantz

AU - Mølgaard, Cecilie

AU - Troelsen, Anders

AU - Hölmich, Per

AU - Barfod, Kristoffer Weisskirchner

N1 - Publisher Copyright: © 2021, The Author(s).

PY - 2021

Y1 - 2021

N2 - Background: Osteoarthritis is a destructive joint disease that leads to degeneration of cartilage and other morphological changes in the joint. No medical treatment currently exists that can reverse these morphological changes. Intra-articular injection with autologous, micro-fragmented adipose tissue has been suggested to relieve symptoms. Methods/Design: The study is a blinded randomized controlled trial with patients allocated in a 1:1 ratio to 2 parallel groups. Patients suffering from pain and functional impairment due to osteoarthritis Kellgren-Lawrence grades 2–3 in the tibiofemoral joint are eligible for inclusion. The intervention group is treated with an intra-articular injection with autologous, micro-fragmented adipose tissue prepared using the Lipogems® system. The control group receives an intra-articular injection with isotonic saline. In total, 120 patients are to be included. The primary outcome is The Knee injury and Osteoarthritis Outcome Score (KOOS4) evaluated at 6 months. Secondary outcomes are KOOS at 3, 12 and 24 months; the Tegner activity score; treatment failure; and work status of the patient. The analysis will be conducted both as intention-to-treat and per-protocol analysis. Discussion: This trial is the first to investigate the efficacy of autologous, micro-fragmented adipose tissue in a randomized controlled trial. The study uses the patient-reported outcome measure Knee Injury and Osteoarthritis Outcome Score (KOOS4) after 6 months as the primary outcome, as it is believed to be a valid measure to assess the patient’s opinion about their knee and associated problems when suffering from osteoarthritis.

AB - Background: Osteoarthritis is a destructive joint disease that leads to degeneration of cartilage and other morphological changes in the joint. No medical treatment currently exists that can reverse these morphological changes. Intra-articular injection with autologous, micro-fragmented adipose tissue has been suggested to relieve symptoms. Methods/Design: The study is a blinded randomized controlled trial with patients allocated in a 1:1 ratio to 2 parallel groups. Patients suffering from pain and functional impairment due to osteoarthritis Kellgren-Lawrence grades 2–3 in the tibiofemoral joint are eligible for inclusion. The intervention group is treated with an intra-articular injection with autologous, micro-fragmented adipose tissue prepared using the Lipogems® system. The control group receives an intra-articular injection with isotonic saline. In total, 120 patients are to be included. The primary outcome is The Knee injury and Osteoarthritis Outcome Score (KOOS4) evaluated at 6 months. Secondary outcomes are KOOS at 3, 12 and 24 months; the Tegner activity score; treatment failure; and work status of the patient. The analysis will be conducted both as intention-to-treat and per-protocol analysis. Discussion: This trial is the first to investigate the efficacy of autologous, micro-fragmented adipose tissue in a randomized controlled trial. The study uses the patient-reported outcome measure Knee Injury and Osteoarthritis Outcome Score (KOOS4) after 6 months as the primary outcome, as it is believed to be a valid measure to assess the patient’s opinion about their knee and associated problems when suffering from osteoarthritis.

KW - Biologic treatment

KW - Knee osteoarthritis

KW - Micro-fragmented adipose tissue

KW - MSCs

KW - Pericyte

KW - Randomized controlled trial

KW - Stemcell

U2 - 10.1186/s13063-021-05628-4

DO - 10.1186/s13063-021-05628-4

M3 - Journal article

C2 - 34706757

AN - SCOPUS:85117899540

VL - 22

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 748

ER -

ID: 284028919